When: Price breaches $96 (structural break of recovery thesis, ~2x ATR below current)

Then: Exit remaining position

HOLD (with optional 10% trim only if concentration reduction is required)

• Forward P/E of 18.4x is appropriate because institutional buyers already normalize for acquisition-related amortization charges rather than being surprised by GAAP optics
• Trailing twelve-month FCF of $7.2B demonstrates earnings power is intact mid-integration, with operating cash flow only down 7% YoY in Q1 2026
• RSI reading of 73 represents a category error when applied to a zero point five eight beta Dividend Aristocrat with fifty three years of dividend growth
• Dividend raised 7% YoY in Q1 2026 with FCF covering dividend 1.8 times and investment grade balance sheet
• $1.35B buyback tranche signals management views stock as approximately 10% undervalued; deleveraging pause is disciplined capital allocation not bearish sentiment
• Google partnership affects present-tense valuation multiple on FreeStyle Libre and Lingo through expanded terminal value assumptions, not just 2028+ revenue
• Soft landing macro regime (8% recession probability, falling yields) historically accelerates defensive dividend payer outperformance
• Technical trend recently turned bullish across fifty and two hundred day moving averages, making trim levels of $102-105 and $98 unlikely to be reached
• FreeStyle Libre dominates prescription CGM market globally while Lingo plus Google targets consumer wellness segment, a different category than DXCM clinical CGM
• Worst-case Lingo underperformance scenario represents single digit percentage impact on total enterprise value in a four-segment diversified company

→ vs aggressive: Aggressive analyst cites 86% probability of zero Fed cuts as multiple headwind but ignores the 8% recession probability and falling yields that define soft landing regime where defensives outperform due to investor rotation from cyclicals into quality

→ vs aggressive: Aggressive analyst treats Wolfe upgrade as exhausted single-quarter catalyst rather than a twelve to twenty four month relative earnings power and balance sheet quality thesis that typically runs for multiple quarters as institutional capital reallocates

→ vs aggressive: Aggressive analyst frames trim levels at $102-105 and $98 as disciplined risk management but ignores the 15-20% upside left on table if stock grinds to $115-120 on earnings normalization, with opportunity cost of holding cash at 4.5% in money market

→ vs aggressive: Aggressive analyst presents the $1.35B buyback tranche as neutral evidence while ignoring that it signals 10% undervaluation; cherry-picking deleveraging as bearish while ignoring repurchase as bullish misrepresents the capital allocation decision

→ vs aggressive: Aggressive analyst overweights Dexcom competitive dynamic in a four-segment diversified company where worst-case Lingo underperformance has single digit percentage impact on total enterprise value

SELL (partial trim of 12-15%)

• RSI at 73 sitting on upper Bollinger Band with price rejecting 114-115 zone for fourth time in a month
• TTM P/E at 36 times versus forward multiple of 18.4 times suggests market has already adjusted for amortization mechanics
• Trailing twelve month FCF of 7.2 billion mid-integration is strong signal; dividend coverage at 1.8 times is comfortable
• Sequential buyback run rate dropped 86 percent but management still committed roughly 1.25 billion in repurchases while deleveraging after 20 billion dollar deal
• Dexcom up 52 percent in three months represents single product line dynamic, not existential competitive threat to diversified four-segment company
• Beta of 0.58 with bullish technical trend across 50 and 200 day moving averages makes aggressive re-entry targets unrealistic
• Wolfe upgrade already moved price 28 percent; trade is partly in the rearview mirror
• Concentration risk not being addressed by conservative thesis; full position into 28 percent rally at resistance is concentration risk masquerading as conviction
• Recommended trim of 12-15 percent creates 3-4 percent dry powder pool for opportunistic redeployment
• Proposed stop loss at 96 is approximately 2 times ATR below current price and well below 200 day moving average at 106
• Re-entry framework: add half position at 106-108 (200 SMA and 10 EMA zone), add remainder at 102-104
• Trim execution should occur in tranches over 2-3 sessions in the 110-113 zone rather than trying to catch exact top

→ vs aggressive: EPS revision thesis is not a revelation as assumed; institutional buyers already run adjusted EPS frameworks that normalize for non-cash charges, and the 18.4x forward versus 36x TTM gap proves the market has already priced amortization

→ vs aggressive: Buyback reduction framed incorrectly as structural reduction in bid-side support when management reallocated roughly 1.25 billion in repurchases toward deleveraging after a 20 billion deal, which represents reallocation of conviction not lack of conviction

→ vs aggressive: Dexcom threat is overweighted; ABT is a four-segment diversified company and even worst-case Lingo scenario represents single-digit percentage impact on total enterprise value

→ vs aggressive: Re-entry targets of 102-105 or 98-100 are too aggressive given 0.58 beta, bullish technical structure, and soft landing regime where ABT could grind sideways and then rip toward 117-120 on next positive print, leaving the 25-35 percent trimmed position earning 4.5 percent while missing 10-15 percent upside

→ vs conservative: Inaction is the most dangerous stance; waiting for 200 DMA near 106 to confirm what technicals are already telling now is passive not conservative, and that approach failed defensive income holders in 2000 and 2008

→ vs conservative: Concentration risk is being ignored; holding full position into 28 percent rally at resistance with elevated allocation is concentration risk masquerading as conviction

→ vs conservative: Google partnership value overstated; calling a multi-year AI commercialization deal a near-term valuation catalyst requires believing equity markets efficiently price optionality today, which they do not

→ vs conservative: Wolfe upgrade is less definitive than presented; Wolfe specifically downgraded Stryker and upgraded ABT, meaning the trade is already 28 percent in the rearview mirror